The Number That Could Test Johnson & Johnson Stock
The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.
For a company of its scale, Johnson & Johnson (JNJ) is telling an ambitious story. Management says it is on track for $100 billion in annual revenue and has a line of sight to double-digit growth by the end of the decade. After a strong quarter where the company grew double-digits, excluding the impact of its declining drug STELARA, that confidence seems warranted.
But this new chapter relies on near-flawless execution from a new generation of blockbuster therapies. For investors, this raises the stakes on a handful of key products. The one number that may deserve the most scrutiny right now is the growth rate of CARVYKTI, a cutting-edge cell therapy for multiple myeloma.
Why Growth Rate Isn’t Purely Good News
On the surface, CARVYKTI’s performance looks spectacular. The drug posted sales of approximately $600 million in the most recent quarter, a year-over-year growth rate of 57.4%. That is, by any standard, a powerful launch for a critical new oncology asset.
The concern is more subtle. That impressive 57.4% growth represents a slight but notable deceleration from the 63.2% growth rate the company reported for CARVYKTI in the prior quarter. For a drug in its critical ramp-up phase, where the market generally expects accelerating momentum, any cooling in the growth rate is a signal worth watching. It’s the first statistical hint that the path to becoming a multi-billion-dollar pillar of the company might not be a straight, steep line upward.
What’s At Stake If CARVYKTI’s Ramp Moderates
A slowdown for CARVYKTI would extend beyond the oncology portfolio, challenging the feasibility of the company’s entire long-term growth narrative. That promise of future double-digit growth is predicated on new products like CARVYKTI delivering on very high expectations. If its trajectory flattens sooner than anticipated, it puts immense pressure on other pipeline drugs to overperform.
This risk is magnified by the stock’s current valuation. With a price-to-sales multiple of 5.9, the stock is trading near its 10-year high of 6.1. A multiple at this level suggests the market is already pricing in a great deal of success from the pipeline. Should a key growth engine like CARVYKTI show signs of decelerating, investors may begin to question whether that premium valuation is still justified.
The absolute sales figures for CARVYKTI will likely remain impressive for some time. The number for you to watch, however, is not the dollar amount but the year-over-year growth percentage. If that 57.4% rate continues to tick down in the coming quarters, it could be the first concrete sign that Johnson & Johnson’s ambitious growth story is encountering tangible headwinds.
Who Is Watching The Other Thirty Risks?
This is one number on one stock. Every name you own has its own version, a quiet metric that could turn, and almost no one has the time to track them all. That is the work behind the Trefis High Quality (HQ) Portfolio: 30 high-quality businesses monitored and re-balanced with discipline, so no single name, Johnson & Johnson included, carries an outsized share of your outcome. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. If keeping watch on risks like this one feels like a lot, a disciplined alternative is worth a serious look today.